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Abstract
Accumulating evidence suggest that apoptosis, autophagy and dysregulation of signaling pathways are common mechanisms
involved in Parkinson’s disease (PD) pathogenesis, and thus development of therapeutic agents targeting these mechanisms may
be useful for the treatment of this disease. Although rutin (a bioflavonoid) is reported to have pharmacological benefits such as
antioxidant, anti-inflammatory and antitumor activities, there are very few reports on the activity of this compound in 1-methyl-4-
phenylpyridinium (MPP+)-induced PD models. Accordingly, we investigated the effects of rutin on apoptosis, autophagy and
cell signalingmarkers (AKT/AMPK) in SH-SY5Y cells exposed toMPP+. Results show reduced changes in nuclear morphology
and mitigation of caspase 3/7 and 9 activities in rutin pre-treated cells exposed to MPP+. Likewise, rutin regulated cell signaling
pathways (AKT/AMPK) and significantly decreased protein expression levels of cleaved PARP, cytochrome c, LC3-II and p62.
Also, rutin significantly increased protein expression levels of full-length caspase 3 in SH-SY5Y cells treated with MPP+.
Transmission electron microscope (TEM) images demonstrated a reduction in autophagosomes in rutin-pretreated SH-SY5Y
cells exposed to MPP+. These results provide experimental support for rutin’s neuroprotective activity against MPP+-induced
toxicity in SH-SY5Y cells, which is as a promising therapeutic agent for clinical trials in humans.
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Introduction
Parkinson’s Disease (PD) is the second most common neuro-
degenerative disorder following Alzheimer’s disease (Reeve
et al. 2014). Although the pathogenesis of PD is not entirely
understood, aging, genetic susceptibility, inflammation and
apoptosis have been implicated (Chiang et al. 2017;
Enogieru et al. 2018a; Inamdar et al. 2007). There is also
evidence suggesting that autophagy plays a critical role in
the progression of PD (Nixon 2013; Pan et al. 2009).
Therefore, a better understanding of the involvement of apo-
ptosis and autophagy might help in the search for new and
efficient treatment options for PD.
Apoptosis is a form of programmed cell death associated
with PD pathophysiology (Erekat 2018; Venderova and Park
2012). Molecular findings linked to apoptosis have been pre-
viously described in post-mortem PD tissues, such as in-
creased caspase-3 activity in the Substantia Nigra pars
compacta (SNpc) of the midbrain (Hartmann 2004). On the
other hand, autophagy involves the degradation of cellular
constituents in autophagolysosomes, initiated by sequestra-
tion of intracellular components in autophagosomes which is
then fused with lysosomes (Yorimitsu and Klionsky 2005).
Although autophagy removes long-lived proteins and im-
paired organelles, it can also act as a survival mechanism in
stress conditions (White 2008). When autophagy is initiated
incorrectly, and is extensive, it acts as a cell-death pathway
(Ghavami et al. 2010; Maycotte and Thorburn 2011). Thus,
autophagy can either maintain neuronal homeostasis or result
in neuronal loss when extensively activated (Batlevi and La
Spada 2011; Lee 2012).
Various intracellular signaling cascades exist in all eukary-
otic cells playing vital roles in several cellular activities. For
instance, the PI3K/AKT pathway controls cellular activities
like neuronal cell proliferation, migration and plasticity
(Amini-Khoei et al. 2019; Jha et al. 2015). Activation of the
PI3K/AKT pathway encourages cell survival, although sever-
al mechanisms involving PI3K/AKT and their association
with progressive neurodegeneration remains an area of active
focus in PD research (Jha et al. 2015). AMPK is a sensor of
AMP:ATP ratio facilitating adaptive measures in response to
low energy conditions (Rosso et al. 2016). AMPK regulates
the whole organism and is linked to neuronal proliferation and
differentiation, synaptic connectivity, and neuroprotection
(Rosso et al. 2016). Previous reports suggest that AMPK has
a crucial role in the pathophysiology of PD owing to its acti-
vation during oxidative stress and autophagy conditions
(Arsikin et al. 2012; Hardie 2007).
Bioactive compounds targeting the impaired AKT/AMPK
balance could meaningfully contribute to neuroprotection in
PD-challenged brains. One such compound is rutin, a flavo-
noid glycoside, abundant in buckwheat, vegetables and fruit
(Enogieru et al. 2018b; Enogieru et al. 2018c). It has been
studied for its numerous pharmacological properties such as
antidepressant (Anjomshoa et al. 2020), anticarcinogenic
(Perk et al. 2014), anti-inflammatory (Yoo et al. 2014) and
cytoprotective effects (Magalingam et al. 2016). Concerning
neuroprotection, rutin has been shown to protect against tox-
icity induced by 1-methyl-4-phenylpyridinium (MPP+), 6-
hydroxydopamine (6-OHDA) and rotenone (Enogieru et al.
2019;Magalingam et al. 2013; Park et al. 2014). However, the
activity of rutin on AKT/AMPK signaling and autophagy in a
MPP+ − induced model of PD has not been investigated.
Accordingly, and for the first time, the present study investi-
gated such activity. In addition, intracellular apoptotic activity
was investigated using assay-based kits and flow cytometry,
changes in nuclear morphology was demonstrated using
Hoechst fluorescence staining, ultrastructural changes in mor-
phology and autophagy was evaluated using the transmission
electron microscope, and changes in protein expression levels
of apoptotic, autophagic and cell signaling markers were stud-
ied in untreated and treated SH-SY5Y cells.
Materials and methods
Cell culture and reagents
SH-SY5Y neuroblastoma cells initially purchased from the
American Type Culture Collection (ATCC, Rockville, MA),
was provided by Dr. AM Serafin (Division of Radiobiology,
Stellenbosch University, South Africa). SH-SY5Y cells were
maintained in Dulbecco’s modified Eagle medium (DMEM)
(Life Technologies, USA), supplemented with 10% Fetal bo-
vine serum (FBS) (Life Technologies, USA) and 1% penicillin-
streptomycin (Lonza, USA), at 37 °C, 5% CO2 in a humidified
incubator. In the cell culture experiments, fresh stock solutions
of MPP+ (purity ≥98% HPLC; Sigma Aldrich, St. Louis, MO,
USA) were prepared in un-supplemented DMEM and used at a
final concentration of 1 mM. Rutin (C27H30O16; purity ≥94%
HPLC) was purchased from Sigma-Aldrich (St. Louis, MO,
USA) without further purification, and fresh stock solutions
were prepared in dimethyl sulfoxide (DMSO, Life
Technologies, USA) and diluted in culture media at final con-
centrations of 25 μM, 50 μM and 100 μM.
Cell toxicity and viability assays
The ApoTox-Glo™ Triplex Assay (Promega, USA) was uti-
lized in this study to assess cytotoxicity and caspase activation
actions. SH-SY5Y cells were seeded at a density of 5.0 × 103
/well in white-walled 96 well plates and were allowed to at-
tach for 24 h. Cells were pre-treated with complete culture
media supplemented with 25 μM, 50 μM or 100 μM of rutin
for 4 h and then treated with 1 mM ofMPP+ for a total of 48 h.
The concentration and duration for MPP+ was selected to
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establish the in vitro PD model as previously reported
(Enogieru et al. 2020; Kumar et al. 2013; Zhao et al. 2020).
After treatment, toxicity experiments were performed accord-
ing to manufacturer’s instructions, and fluorescence was mea-
sured using the GloMax™ Multiscan plate reader (Promega,
USA) at the wavelength sets of 490Ex/510-570Em.
The trypan blue dye exclusion test was used to evaluate the
population of viable/live cells present in a cell suspension. In
this assay, viable/live cells possessing intact cell membranes
block entry of the dye and thus prevent cell staining (Strober
1997). SH-SY5Y cells were seeded at a density of 1.6 × 104
/cm2 in 60 mm dishes and were allowed to attach for 24 h.
After that, supernatants were discarded, and cells were treated
as described in section 2.2.1. Adherent cells were detached by
trypsinization, pelleted, and resuspended in fresh media. A
total of 10 μl of cell suspension was added to an equivalent
volume of 0.4% trypan blue dye (Sigma Aldrich, St. Louis,
MO, USA) and loaded into a BioRad TC20™ automated cell
counter. Viability was expressed as the percentage of total cell
count that were viable/live cells.
Estimation of Caspase-3 activation and Caspase-9
activity
After fluorescence reading from the cytotoxicity experiment
using the ApoTox-Glo assay kit in section 2.2.1, estimation of
caspase 3/7 activation was performed according to the instruc-
tions of the manufacturer, and luminescence was measured
using the GloMax™ Multiscan plate reader.
The ApoTarget™ Caspase-9 Protease Assay (Life
Technologies, USA) was utilized in this study to measure
caspase-9 proteolytic activity. SH-SY5Y cells were seeded at a
density of 1.2 × 105 /ml in 100-mm dishes and were allowed to
attach for 24 h. Following treatment with rutin and MPP+ as
described in section 2.2.1, measurements of caspase-9 activity
were performed according to manufacturer’s instructions, and
absorbance was read using a Polarstar Omega plate reader
(BMG Labtech, USA) at 405 nm.
Flow cytometric evaluation of apoptosis
The FITC Annexin V/Dead cell apoptosis kit (Life
Technologies, USA) was utilized in this study to assay for
apoptosis. Upon cellular staining with FITC Annexin V and
PI, apoptotic and dead cells fluoresce in green and red while
viable cells do not fluoresce. SH-SY5Y cells were seeded at a
density of 1.2 × 105 /ml in 100mm dishes and were allowed to
attach for 24 h. Following treatment with rutin and MPP+ as
described in section 2.2.1, experiments were performed ac-
cording to the manufacturer’s instructions. Stained cell sus-
pensions were analyzed using a BD FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, New Jersey,
USA) to measure red and green fluorescence, with a total of
10,000 events collected for each sample. Fluorescence acqui-
sition, compensation and data analysis were performed ac-
cording to the manufacturer’s instructions.
Nuclear staining with Hoechst 33342
Hoechst 33342 nucleic acid stain (Life Technologies, USA)
was utilized in this study to demonstrate apoptotic cells.
Briefly, cells were seeded at a density of 1.1 × 105 /ml in
60 mm dishes and were allowed to attach for 24 h.
Following treatment with rutin and MPP+ as described in sec-
tion 2.2.1, experiments were performed according to the man-
ufacturer’s instructions and cells were viewed for fluorescent
imaging using a Zeiss Axio-plan 2 fluorescent microscope
(Zeiss, Germany).
Western blot
Western blots were used to evaluate the effects of rutin treat-
ment on protein markers of apoptosis, autophagy and cell
signaling. Following treatment with rutin and MPP+ as de-
scribed in section 2.2.1, proteins were prepared for blocking
with the relevant primary antibody as previously reported by
our laboratory (Enogieru et al. 2019). Primary antibodies in-
cluded full-length caspase 3 (rabbit polyclonal, 1:1000, Cell
Signalling Technology, USA). cleaved poly (ADP-ribose) po-
lymerase (PARP; rabbit polyclonal, 1:1000, Cell Signalling
Technology), LC3 (rabbit monoclonal, 1:2000, Cell
Signalling Technology), SQSTM1/p62 (rabbit polyclonal,
1:1000, Cell Signalling Technology), phospho-Akt (rabbit
monoclonal, 1:1000, Cell Signalling Technology), phospho-
AMPK (rabbit monoclonal, 1:500, Cell Signalling
Technology), loading control GAPDH (rabbit polyclonal,
1:1000; Santa Cruz Biotechnology, USA). Membranes were
incubated with appropriate HRP-conjugated secondary anti-
bodies (1:5000, Santa Cruz Biotechnology, USA) and visual-
ized using a SuperSignal® West Pico Chemiluminescent kit
(Thermo Scientific, USA). Image J software (http://imagej.
nih.gov/ij/) was utilized to quantify western blots by means
of densitometric measurements.
Transmission electron microscopy
SH-SY5Y cells were seeded at a density of 1.2 × 105 /ml in
100 mm dishes and were allowed to attach for 24 h.
Following treatment with rutin and MPP+ as described in sec-
tion 2.2.1, cells were centrifuged in ice-cold PBS at 3000 rpm
for 5 min, fixed in 500 μL of 2.5% phosphate-buffered glutar-
aldehyde and post-fixed in 1% osmium tetroxide in the same
buffer. The fixed samples were subsequently processed for
transmission electron microscopy. A Reichert ultramicrotome
(SMM Instruments, Johannesburg, South Africa) with a dia-
mond knife (Agar Scientific, Randburg, South Africa) was used
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to make silver to gold sections. Thin sections on copper grids
were examined using a Jeol JEM 1011 transmission electron
microscope at 80 kV (Advanced Laboratory Solutions,
Johannesburg, South Africa). Electron micrographs were pro-
duced with a Mega View III digital camera fitted onto the
microscope and by means of the ITEM software package
(Advanced Laboratory Solutions, Johannesburg, South Africa).
Statistical analysis
GraphPad Prism Software V7 was used for all statistical anal-
yses (www.graphpad.com/scientific-software/prism/). Data
are expressed as mean with standard error of mean (SEM).
One-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparisons post-hoc test was performed to deter-
mine statistical significance (p < 0.05).
Results
Rutin inhibits cell toxicity in MPP+ treated SH-SY5Y
cells
To assess the protective activity of rutin on MPP+ induced
SH-SY5Y cell toxicity, cells were pretreated with three con-
centrations of rutin (25, 50 and 100 μM) before being exposed
to 1 mM MPP+ as described earlier. Our results revealed that
treatment of SH-SY5Y cells with MPP+ resulted in a signifi-
cant increase (p < 0.0001, Fig. 1a) in cell toxicity; however,
pretreatment of SH-SY5Y cells with rutin significantly re-
duced toxicity at concentrations of 25 μM (p = 0.0016);
50 μM (p = 0.0025) and 100 μM (p = 0.0001) respectively.
Similarly, all concentrations of rutin significantly increased
(p < 0.0001, Fig. 1b) cell viability when compared to cells
treated with MPP+ only.
Rutin inhibits caspase-3/7 activation and attenuates
caspase-9 activity in SH-SY5Y cells treated with MPP+
To establish whether the effector caspase-3/7 are initiated in
this model of PD, caspase-3/7 activation was investigated in
treated and control SH-SY5Y cells. Findings show that where-
as treatment with MPP+ significantly increased (p < 0.0001,
Fig. 2a) caspase 3/7 activation, all concentrations of rutin sig-
nificantly reduced (p < 0.0001) caspase 3/7 activation. Next,
the activity of caspase 9 was investigated in treated and con-
trol SH-SY5Y cells. Our findings reveal a significant increase
(p < 0.0001, Fig. 2b) in the activity of caspase 9 in cells treated
with MPP+ only, however, pretreatment with rutin resulted in
a significant decrease in the activity of caspase 9 at concen-
trations of 25 μM (p = 0.0060); 50 μM (p = 0.0044) and
100 μM (p = 0.0006) respectively.
Rutin inhibits apoptosis inMPP+ treated SH-SY5Y cells
detected by flow cytometry
A flow cytometric analysis was performed to evaluate apoptotic
activity in control and treated SH-SY5Y cells. Figure 3. shows a
demonstration of PI versus V-FITC fluorescence. The lower left
quadrant signifies the live cells and the lower right quadrant
signifies the early apoptotic cells. The upper right quadrant sig-
nifies the late apoptotic cells while the upper left quadrant sig-
nifies the necrotic cells. Findings show that in the control SH-
SY5Y cells, 13.53% of cells were bound to annexin V-FITC,
indicating low apoptotic activity. In cells treatedwithMPP+ only,
44.81% of the cells bound to annexin V-FITC indicating a sig-
nificant increase (p < 0.0001) in apoptotic activity. Conversely,
following rutin pretreatment in SH-SY5Y cells, it was observed
that significantly fewer cells bound to annexin V-FITC at con-
centrations of 25 μM (32.95%, p = 0.0066); 50 μM (27.63%,
p = 0.0004) and 100 μM (22.38%, p < 0.0001).
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Fig. 1 Cell toxicity (a) and viability (b) in treated and control SH-SY5Y cells. Bars represent the mean ± SEM from three separate experiments.
#P < 0.0001 vs control SH-SY5Y cells; **P < 0.005, ***P < 0.0005 and ****P < 0.0001 vs SH-SY5Y cells treated with MPP+ only
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Nuclear morphology in control and treated SH-SY5Y
cells
Changes in nuclear morphology were investigated using
Hoechst 33342 staining. Obtained images showed that nuclei
of control SH-SY5Y cells displayed a normal oval shape,
while nuclei of cells treated with MPP+ displayed features of
apoptosis typically characterized by nuclear fragmentation
and condensation. On the other hand, the SH-SY5Y cells
pretreated with rutin did not display these apoptotic features
(Fig. 4).
Rutin inhibits MPP+ triggered reduction of full-length
caspase 3 and activation of cleaved PARP
Western blots were used to detect protein expression levels of
full-length caspase 3 and results obtained showed that treat-
ment of SH-SY5Y cells with MPP+ alone resulted in a
Fig. 3 Representative flow cytometric dot plots showing the effect of
rutin on MPP+-induced apoptosis. (a). Control SH-SY5Y cells (b) SH-
SY5Y cells treated with MPP+ only (c) SH-SY5Y cells treated with
25 μM rutin and then treated with MPP+ (d) SH-SY5Y cells treated with
50 μM rutin and then treated with MPP+ (e) SH-SY5Y cells treated with
100 μM rutin and then treated with MPP+ (f) Graph showing the total
apoptotic activity in control and treated SH-SY5Y cells. Bars represent
the mean ± SEM from three separate experiments. # P < 0.0001 vs control
SH-SY5Y cells; *P < 0.05, **P < 0.005 and ***P < 0.0005 vs SH-SY5Y
cells treated with MPP+ only
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Fig. 2 Caspase-3/7 activation (a) and Caspase-9 activity (b) in treated and control SH-SY5Y cells. Bars represent the mean ± SEM from three separate
experiments. # P < 0.0001 vs control SH-SY5Y cells; **P < 0.005, ***P < 0.0005 and ****P < 0.0001 vs SH-SY5Y cells treated with MPP+ only
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significant decrease in the expression of full-length caspase 3
(p = 0.0005, Fig. 5a). Following pretreatment of SH-SY5Y
cells with rutin, the expression levels of full-length caspase 3
were significantly increased at concentrations of 25 μM (p =
0.0205); 50 μM (p = 0.0051) and 100 μM (p = 0.0026) re-
spectively. The decrease in the full-length caspase 3 appears
to confirm the previous results on the activation of caspase 3/7
in SH-SY5Y cells treated with MPP+ only. Conversely, the
increase in the expression levels of full-length caspase 3 fol-
lowing rutin pretreatment could also be confirmation of the
previous results on the ability of rutin to inhibit caspase 3
activity in MPP+ treated SH-SY5Y cells.
Next, to determine whether the effector caspases activate
PARP, western blots were utilized to detect expression levels
of cleaved PARP. Following quantification of western blot
images, treatment of SH-SY5Y cells with MPP+ only resulted
in a significant increase in the expression of cleaved PARP
(p < 0.0001, Fig. 5b), thus indicating increased apoptosis in
these cells. Conversely, when the cells were pretreated with all
concentrations of rutin, a significant reduction in the
Fig. 4 Fluorescence micrographs of Hoechst 33342 stained nuclear
morphology. (a) Control SH-SY5Y cells (b) SH-SY5Y cells treated with
MPP+ only (c) SH-SY5Y cells pretreated with 25 μM rutin and then
treated with MPP+ (d) SH-SY5Y cells pretreated with 50 μM rutin and
then treated with MPP+ (E) SH-SY5Y cells pretreated with 100 μM and
then treated with MPP+. Arrows indicate apoptotic cells. Scale bar indi-
cates 100 μM
Fig. 5 Rutin prevents MPP+ induced apoptosis in SH-SY5Y cells. (a)
Protein expression of full-length caspase-3 following treatment (b)
Protein expression of cleaved PARP following treatment. Data is present-
ed as the ratio of the target protein and GAPDH loading control. Bars
represent the mean relative band intensity ± SEM for three separate ex-
periments. #P < 0.0001 vs control cells; *P < 0.05, **P < 0.005 and
****P < 0.0001 vs cells treated with MPP+ only
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expression levels of cleaved PARP (p < 0.0001) was ob-
served, suggesting decreased apoptosis and also confirming
the previous finding that rutin inhibits MPP+-induced apopto-
sis in SH-SY5Y cells.
Rutin inhibits abnormal autophagy activation in SH-
SY5Y cells treated with MPP+
Western blots were used to detect expression levels of
autophagosome-linked LC3-II, a widely used marker of au-
tophagy (Kabeya et al. 2000). Findings revealed that treatment
of SH-SY5Y cells withMPP+ resulted in a significant increase
in the expression levels of LC3-II (p < 0.0001, Fig. 6a).
Autophagic activity was significantly reduced in rutin
pretreated SH-SY5Y cells at concentrations of 25 μM (p =
0.0473); 50 μM (p = 0.0320) and 100 μM (p = 0.0092)
respectively.
p62 is an autophagy marker known to link ubiquitinated
proteins to LC3 for degradation via autophagy (Pankiv et al.
2007). p62 is an important indicator of autophagy because its
accumulation is unusually elevated when there is a block or
defect in the activation of autophagy (Lynch-Day et al. 2012).
Treatment of SH-SY5Y cells with MPP+ only resulted in a
significant increase in the expression of p62 in SH-SY5Y cells
(p = 0.0001, Fig. 6b). However, p62 activity was significantly
reduced in rutin pretreated SH-SY5Y cells at concentrations
of 25 μM (p = 0.0050); 50 μM (p = 0.0055) and 100 μM (p =
0.0083) respectively.
TEM evaluation of control and treated SH-SY5Y cells
To further verify the findings from western blots in section
3.6, transmission electron microscopy (TEM) was utilized to
examine autophagy and ultrastructural changes in the
morphology of control and treated SH-SY5Y cells. TEM im-
ages revealed the presence of autophagy in treated SH-SY5Y
cells (Fig. 7). Cells treated with MPP+ only contained numer-
ous autophagic vacuoles (with more visible autophagosomes),
showed distorted mitochondria structure, mitochondrial swell-
ing and rupturing cristae in the electron micrographs. The
general ultrastructure in rutin pretreated SH-SY5Y cells
showed markedly improved mitochondrial architecture, as
well as fewer autophagosomes when compared to the SH-
SY5Y cells treated with MPP+ only.
Rutin regulates the AKT/AMPK signaling pathways in
SH-SY5Y cells treated with MPP+
Earlier studies have established that AKT mediates pro-
survival effects when cells are exposed to various apoptotic
stimuli (Kim and Park 2018; Zhao et al. 2016). Findings re-
vealed that treatment of SH-SY5Y cells with MPP+ only re-
sulted in a significant decrease (p = 0.0028, Fig. 8a) in the
expression of p-AKT, thus indicating that there was downreg-
ulation of pro-survival signaling. Conversely, following pre-
treatment of SH-SY5Y cells with rutin, a significant increase
in the expression of p-AKT was observed at concentrations of
25 μM (p = 0.0283), 50 μM (p = 0.0400) and 100 μM (p =
0.0002) respectively, possibly indicating an upregulation of
pro-survival signaling in MPP+-treated SH-SY5Y cells. This
could be linked to the potential neuroprotective effects of rutin
against MPP+ induced apoptosis and cell death.
AMPK is a molecular measure of energy status and be-
comes activated during oxidative stress, autophagy and other
conditions that lead to the depletion of cellular energy (Ju et al.
2014; Wen et al. 2018). Findings revealed that treatment of
SH-SY5Y cells with MPP+ only resulted in a significant in-
crease in the expression of pAMPKα (p = 0.0004, Fig. 8b).
Fig. 6 Rutin prevents MPP+ induced aberrant activation of autophagy in
SH-SY5Y cells. (a) Protein expression of LC3-II following treatment (b)
Protein expression of p62 following treatment. Data is presented as the
ratio of the target protein and GAPDH loading control. Bars represent the
mean relative band intensity ± SEM for three separate experiments.
#P < 0.0001 vs control cells; *P < 0.05, and **P < 0.005 vs cells treated
with MPP+ only
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Following pretreatment of SH-SY5Y cells with rutin, a signif-
icant reduction in the expression of pAMPKαwas observed at
concentrations of 25 μM (p = 0.0040); 50 μM (p = 0.0193)
and 100 μM (p = 0.0007) respectively. These findings indi-
cate that rutin was able to inhibit MPP+-induced activation of
AMPK in SH-SY5Y cells.
Discussion
The present study provides new evidence of the neuroprotec-
tive activity of rutin through its inhibition of apoptosis and
regulation of AKT/AMPK signaling as well as autophagy in
a MPP+-induced PD model. It is reported that apoptosis is a
consequence of activated caspase proteolysis (Serviddio et al.
2011). Caspase-dependent and caspase-independent mecha-
nisms have been proposed as essential mechanisms leading
to dopaminergic neuronal death in the SNpc of PD patients
(Schulz 2006). PARP enzymes are involved in neurodegener-
ative disorders, including PD (Martire et al. 2015). PARP, a
downstream target of caspase-3, is a ubiquitous nuclear en-
zyme involved in DNA repair; however, when PARP levels
are incredibly high, cell death is initiated (Bürkle 2001; Le
et al. 2002). During cell death processes, PARP is cleaved into
Fig. 7 TEM images showing inhibition of MPP+ induced aberrant
autophagy and mitochondrial changes in SH-SY5Y cells pretreated with
rutin. (a) Control SH-SY5Y cells (b) SH-SY5Y cells treated with MPP+
only (c) SH-SY5Y cells pretreated with 25 μM and then treated with
MPP+ (d) SH-SY5Y cells pretreated with 50 μM and then treated with
MPP+ (e) SH-SY5Y cells pretreated with 100 μM and then treated with
MPP+. White arrows indicate healthy mitochondria; black arrows show
different autophagic vacuoles: * represents autophagosomes (with cyto-
plasm); ** represents autophagolysosomes at the late stage of degrada-
tion. Yellow arrows indicate swollen or degrading mitochondria with
distorted or disorganized cristae; blue arrows indicate improved mito-
chondria structure. Scale bar represents 2 μM
Fig. 8 Rutin regulates signaling pathways in SH-SY5Y cells. (a) Protein
expression of p-AKT following treatment (b) Protein expression of
pAMPKα following treatment. Data is presented as the ratio of the target
protein and GAPDH loading control. Bars represent the mean relative
band intensity ± SEM for three separate experiments. #P < 0.0001 vs
control cells; *P < 0.05, **P < 0.005 and ***P < 0.0005 vs cells treated
with MPP+ only
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fragments that are specific to various apoptotic signals. The
action of caspase 3/7 activation most likely produced the 89-
kDa fragment detected in this study, which is in line with
previous reports showing detection of PARP (Kumar et al.
2013; Lu et al. 2017). Different neuroprotective compounds
studied in various PD models have demonstrated their ability
to affect the expression of caspases and PARP. For example,
in PC12 cells, curcumin was reported to inhibit PARP activa-
tion (Raza et al. 2008) and protect against MPP+-induced ap-
optosis (Chen et al. 2006). The polyphenol hesperidin was
also found to reduce caspase-3/9 activities in an in vitro hu-
man SK-N-SH cellular model of rotenone-induced PD
(Tamilselvam et al. 2013). Findings from this study show that
rutin attenuates MPP+ induced neuronal apoptotic death, at
least in part, by down-regulating apoptotic signals such as
caspase 3/7, caspase 9 and cleaved PARP.
Compelling evidence obtained from PD patients and PD
models have helped to unravel the involvement of autophagy
in PD pathogenesis (Cheung and Ip 2011). Reports reveal the
accumulation of autophagic vacuoles in post-mortem brain
tissues of PD patients (Hou et al. 2020; Zhang et al. 2012),
and significant activation of the autophagy response has been
subsequently detected in blood samples from PD patients
(Prigione et al. 2010). Thus, there is growing interest in au-
tophagic deregulation observed in PD since the autophagic
pathway is responsible for the clearance of aberrant proteins.
Many of the neurotoxins used to induce PD also influence the
autophagy pathway, for example, MPP+ causes increased au-
tophagy in SH-SY5Y cells (Zhu et al. 2007). Reports show
that the SNpc of mice treated withMPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) exhibit autophagic cell death (Liu
et al. 2013a; Meredith et al. 2009). While it is agreed that
deficient autophagy activation would impede clearance of
protein aggregates, it is suggested that the magnitude of au-
tophagy produced may determine cell survival, with low
levels linked to homeostatic functions and high levels stimu-
lating cell death, either directly or indirectly (Wang et al.
2009). In line with previous reports (Liu et al. 2013b), we
observe that MPP+ causes aberrant/extreme activation of au-
tophagy in SH-SY5Y cells. This may be due to excessive
autophagic demand in the cells, which could not be balanced
by cellular reserves, thus resulting in cell death. Also, MPP+
may have impaired the membrane integrity of lysosomes lead-
ing to protease leakage that caused damage to other cellular
components (Button et al. 2015). A deficit in lysosomal func-
tion is known to stimulate autophagy, thereby leading to a
pathological accumulation of autophagosomes that cannot be
successfully cleared (Gomez-Suaga et al. 2011). In line with
previous reports (Anglade et al. 1997; Zhu et al. 2003), our
TEM images revealed abnormal accumulation of
autophagosomes in SH-SY5Y cells treated with MPP+ only.
This is in sharp contrast to the infrequent detection of
autophagosomes in control and rutin pretreated SH-SY5Y
cells, probably due to the efficient and speedy clearance of
au tophagic vacuoles . The presence of e leva ted
autophagosomes in our PD model besides signifying a flaw
in the activation of autophagy might be as a result of a defec-
tive clearance which led to its accumulation. This is demon-
strated by the increased expression of both LC3-II and p62
proteins in SH-SY5Y cells treated with MPP+ only. The at-
tenuation of abnormal autophagy activation by rutin provides
the first evidence of its beneficial role in autophagy-related
mechanism in a MPP+ model of PD.
Findings from this study show that rutin pre-treatment pre-
vents MPP+-induced toxicity partly through the regulation of
the AKT signaling pathway. Once activated, the AKT path-
way controls downstream signaling cascades that affect a va-
riety of cellular activities including proliferation, survival, mi-
gration, differentiation, metabolism and polarity in different
cell types including neurons (Greene et al. 2011; Manning and
Cantley 2007; Zhang et al. 2016). Some reports support com-
promised AKT signaling in PD. For example, immunostain-
ing of post-mortem brains reveals that AKT phosphorylation
is significantly reduced in the dopaminergic SNpc of PD pa-
tients when compared with non-PD patients (Timmons et al.
2009). In other studies, AKT phosphorylation was significant-
ly diminished by treatment of neuronal cells with PD neuro-
toxins (Malagelada et al. 2008; Rodriguez-Blanco et al. 2008;
Tasaki et al. 2010), and treatments that inhibit loss of AKT
phosphorylation are protective in such PD models
(Malagelada et al. 2010; Tasaki et al. 2010). Some bioactive
compounds exhibit their neuroprotective properties through
their ability to activate the AKT pathway in various in vitro
models of PD (Fukui et al. 2010; Qin et al. 2011; Tasaki et al.
2010). These reports suggest that most neuroprotective PD
agents share a common characteristic in their ability to im-
prove AKT activation. Accordingly, our findings show that
MPP+ treatment caused a reduction in phosphorylated AKT
levels in SH-SY5Y cells while rutin pre-treatment upregulated
phosphorylated AKT expression and thus inhibited down-
stream cellular activities associated with MPP+ toxicity.
AMPK is considered a key regulator of cellular energy
metabolism (Garcia and Shaw 2017). Activation of AMPK
is regulated by ROS, Ca2+ and cellular AMP/ATP ratio
(Jung et al. 2008; Park et al. 2006), and has a range of effects
that may be relevant to PD such as mitochondrial quality
control, changes in cellular metabolism, promotion of autoph-
agy, reduced inflammation and improved antioxidant capacity
(Choi et al. 2010). Conversely, reports show that AMPK also
plays a role in facilitating progragmmed cell death, particular-
ly in situations of bioenergetic failure or severe cellular stress.
Previous studies show that activation of AMPK by PD-
inducing neurotoxins promotes neuronal death by facilitating
excessive autophagy and impaired protein synthesis (Xilouri
and Stefanis 2011; Xu et al. 2014). Findings from this study
agree with previous reports (Button et al. 2015; Gomez-Suaga
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et al. 2011; Xu et al. 2014) demonstrating that activation of
AMPK stimulates autophagy and leads to accumulation of
autophagosomes that cannot be successfully cleared.
In conclusion, this study provides new evidence that rutin
attenuates the inhibition of AKT and activation of AMPK in a
MPP+ model of PD. This supports suggestions that a crosstalk
between these signaling pathways leads to the debilitating
effects of MPP+ (Pan et al. 2009; Xu et al. 2014). Future
studies will involve investigating the regulatory activity of
rutin on autophagy and the AKT/AMPK signaling pathway
in MPTP animal models of PD.
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